LeMaitre Vascular, Inc.
LMATHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeLeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. At a $2.32B market cap, LeMaitre Vascular, Inc. ranks as a mid-cap company within healthcare. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services.
Market Cap
$2.32B
Beta
0.52
P/E (TTM)
37.36
P/E (Fwd)
31.22
EPS (TTM)
$2.72
EPS (Fwd)
$3.26
ROE
16.6%
ROA
7.2%
Cash
$367.2M
Total Debt
$189.8M
Free CF
$53.3M
52W Change
27.4%
Annual Financials
Cash vs Debt
With $367.2M in cash and $189.8M in debt, LMAT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $53.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 16.6% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $161.7M (2022) to $249.6M (2025), reflecting a 54% increase over the period.
With a beta below 0.7, LeMaitre Vascular, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LMAT.